Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First‐trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell‐free DNA testing

7 Jun 2013

Abstract excerpt

OBJECTIVE: To define risk cut-offs with corresponding detection rates (DR) and false-positive rates (FPR) in screening for trisomy 21 using maternal age and combinations of first-trimester biomarkers in order to determine which women should undergo contingent maternal blood cell-free (cf) DNA testing. METHODS: From singleton pregnancies undergoing screening for aneuploidies at three UK hospitals between March...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Assisted Reproductive Technology and Twin Pregnancy
Share to Gestational Trophoblastic Disease Studies
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23744626
DOI: 10.1002/uog.12511

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First‐trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell‐free DNA testingPMID 23744626Read ↗

First-Trimester Contingent Screening for Trisomies 21, 18 and 13 by Biomarkers and Maternal Blood Cell-Free DNA TestingSemantic proximity Read ↗

Contingent first‐trimester screening for aneuploidies with cell‐free DNA in a Danish clinical settingSemantic proximity Read ↗

First‐trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell‐free DNA testingSemantic proximity Read ↗

First-Trimester Screening for Trisomies 21, 18 and 13 by Ultrasound and Biochemical TestingSemantic proximity Read ↗

Routine first‐trimester screening for fetal trisomies in twin pregnancy: cell‐free DNA test contingent on results from combined testSemantic proximity Read ↗

Clinical implementation of routine screening for fetal trisomies in the UK NHS : cell‐free DNA test contingent on results from first‐trimester combined testSemantic proximity Read ↗

Screening for trisomies 21, 18 and 13 by cell‐free <scp>DNA</scp> analysis of maternal blood at 10–11 weeks' gestation and the combined test at 11–13 weeksSemantic proximity Read ↗

Analysis of cell‐free <scp>DNA</scp> in maternal blood in screening for fetal aneuploidies: updated meta‐analysisSemantic proximity Read ↗

Clinical application of a contingent screening strategy for trisomies with cell-free DNA: a pilot studySemantic proximity Read ↗

Combined First Trimester Screening and Cell-Free Fetal DNA – “Next Generation Screening”Semantic proximity Read ↗

Noninvasive Prenatal Testing for Fetal Trisomies in a Routinely Screened First-Trimester PopulationSemantic proximity Read ↗

Cell‐free <scp>DNA</scp> testing of maternal blood in screening for trisomies in twin pregnancy: updated cohort study at 10–14 weeks and meta‐analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.